Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PerkinElmer Inc And Verinata Health, Inc Announces Collaboration


Wednesday, 9 Jan 2013 08:02am EST 

PerkinElmer Inc and Verinata Health, Inc., announced a strategic agreement for expanding access to Verinata's verifi test, the comprehensive non-invasive prenatal test (NIPT) currently available for high-risk pregnancies. The verifi test, which is performed at Verinata's CLIA-certified, California laboratory, uses a single maternal blood draw as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies. Chromosomal aneuploidy is an abnormal number of chromosomes. Under the terms of the collaboration agreement, PerkinElmer will serve as an exclusive Verinata Health commercial partner in the joint sales and marketing of the verifi test in the United States. The collaboration consolidates and streamlines delivery of prenatal testing options due to the combination of PerkinElmer's prenatal testing menu with Verinata's technologies for the early, non-invasive identification of specific fetal chromosomal aneuploidies. 

Company Quote

41.13
 --
23 Oct 2014